Articles From: PSEG Long Island Reminds Customers to be Cautious of Scams and Imposters to PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2014 Financial Results


2014/6/26
UNIONDALE, N.Y. , June 26, 2014 /PRNewswire/ -- PSEG Long Island is reiterating its warning to customers to be on alert for phone and email payment scams, and thieves posing as utility workers, which could put their financial and personal security at risk.
Sign-up for PSEG Long Island Reminds Customers to be Cautious of Scams and Imposters investment picks
El Paso Project Is PSEG Solar Source's First Texas Facility NEWARK, N.J. , July 2, 2014 /PRNewswire/ -- PSEG Solar Source announced today that it will acquire a 13 megawatt (MWdc) solar energy facility near El Paso, TX from juwi solar (JSI). The project was originally developed by JSI and has a 30-year power purchase agreement (PPA) with El Paso Electric Company.
Sign-up for PSEG Solar Source to acquire 13 MW Texas Solar Project from juwi investment picks
NEWARK, N.J., July 23, 2014 /PRNewswire/ -- PSEG Solar Source today announced that it will acquire the ERWR Whitcomb Farm Solar project from juwi solar (JSI). The facility, which will now be known as the PSEG Essex Solar Energy Center, has a 25-year power purchase agreement (PPA) with Vermont Electric Power Producers (VEEP), Inc., as part of the Vermont Sustainably Priced Energy Enterprise Development (SPEED) program.
Sign-up for PSEG Solar Source Ventures into Vermont With Acquisition of Solar Facility from juwi investment picks
2014/7/7
Eligible organizations urged to apply by August 15 NEWARK, N.J. , July 7, 2014 /PRNewswire/ -- The PSEG Foundation is accepting applications from afterschool, summer and youth development programs to develop new or enhance existing STEM (Science, Technology, Engineering, and Math) educational opportunities for students.
Sign-up for PSEG to Award $160,000 in Grants to Further STEM Education in NJ investment picks
pSivida Corp.
Sign-up for pSivida Corp. Names James Barry to Board of Directors investment picks
2014/9/9
pSivida Corp.
Sign-up for pSivida Corp. Reports Fourth Quarter and FY 2014 Results investment picks
2014/7/8
PsomasFMG and Constellation today announced an agreement to develop up to 50 megawatts of solar distributed generation projects for California-area schools and municipalities through the end of 2015.
Sign-up for PsomasFMG and Constellation to Develop up to 50 Megawatts of Solar Generation for California Schools and Municipalities investment picks
Declares 72nd Consecutive Quarterly Dividend ACTON, Mass., July 28, 2014 /PRNewswire/ -- Psychemedics Corporation (NASDAQ: PMD) today announced second quarter financial results for the period ended June 30, 2014.
Sign-up for Psychemedics Corporation Announces Record Revenues investment picks
PTC (Nasdaq: PTC) today announced that its Board of Directors has declassified the PTC Board, effective immediately.
Sign-up for PTC Announces Declassification of its Board of Directors investment picks
PTC (Nasdaq: PTC) today announced a new capital allocation strategy that further enhances the company’s focus on sustainable growth and shareholder value.
Sign-up for PTC Announces New Capital Allocation Strategy investment picks
PTC (Nasdaq: PTC) today reported results for its third fiscal quarter ended June 28, 2014.
Sign-up for PTC Announces Q3 Results; Provides Q4 and Updated FY’14 Outlook investment picks
PTC (Nasdaq: PTC) today announced that CFO Jeff Glidden has notified the Company of his intention to retire in FY’15. PTC will engage an executive search firm to initiate a comprehensive search for Mr.
Sign-up for PTC Announces Upcoming Retirement of CFO Jeff Glidden investment picks
PTC (Nasdaq: PTC) has completed its acquisition of Atego , a developer of model-based systems and software engineering applications.
Sign-up for PTC Completes Acquisition of Atego investment picks
PTC (Nasdaq: PTC) today completed its acquisition of Axeda Corporation , a developer of solutions that securely connect machines and sensors to the cloud.
Sign-up for PTC Completes Acquisition of Axeda investment picks
Confirming that progressive support strategies offer business value to both PTC and its customers, PTC (Nasdaq: PTC) today announced the company was named for the second consecutive year a “Top Ten Best Support Website” for 2014 by the Association of Support Professionals (ASP). This designation highlights the company’s commitment to deliver a global support program focused on the customer experience to build stronger relationships and provide real value that drives business success.
Sign-up for PTC Global Support Drives Business Value for Customers investment picks
PTC (Nasdaq: PTC) today announced it has been ranked a leading provider of product lifecycle management (PLM) solutions in China by independent global PLM strategic management consulting and research firm CIMdata, Inc. In its 2014 China PLM Market Report just issued, CIMdata identified PTC as the clear market leader in three categories: collaborative Product Definition management (cPDm), as well as in PLM revenues from the Aerospace & Defense and Electronics & High Tech verticals.
Sign-up for PTC Secures Market Leadership Position Among PLM Solution Providers in China investment picks
-French ATU Cohort and Other Named Patient Programs Authorized - SOUTH PLAINFIELD, N.J. , July 9, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a reimbursed expanded access program (EAP). PTC's EAP program is intended to make Translarna™ (ataluren) available to patients before commercial availability in certain countries.
Sign-up for PTC Therapeutics Announces Expanded Access Program For Translarna™ (ataluren) investment picks
-Top-line data expected H2 2015- -Data intended to support applications for additional approvals globally- SOUTH PLAINFIELD, N.J. , Sept.
Sign-up for PTC Therapeutics Completes Enrollment of Landmark Trial in Duchenne Muscular Dystrophy investment picks
SOUTH PLAINFIELD, N.J. , June 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a global confirmatory Phase 3 clinical trial of Translarna™ (ataluren), an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). Nonsense mutations within cystic fibrosis are categorized as Class I mutations, a severe form of CF that results in little or no production of the CFTR protein.
Sign-up for PTC Therapeutics Initiates Confirmatory Phase 3 Clinical Trial of Translarna™ (ataluren) in Patients with Nonsense Mutation Cystic Fibrosis (nmCF) investment picks
- The first treatment approved for DMD - SOUTH PLAINFIELD, N.J. , Aug.
Sign-up for PTC Therapeutics Receives Conditional Approval in the European Union for Translarna™ For the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy investment picks
SOUTH PLAINFIELD, N.J. , June 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it is the recipient of Parent Project Muscular Dystrophy's (PPMD) "Path to Progress" award, honoring PTC's 16 years of commitment to bring the first-ever therapy for the underlying cause of the disorder to patients with Duchenne muscular dystrophy (DMD). The award was presented at PPMD's Annual Connect Conference in Chicago, Illinois .
Sign-up for PTC Therapeutics Recipient of Parent Project Muscular Dystrophy's "Path to Progress" Award investment picks
SOUTH PLAINFIELD, N.J. , Aug.
Sign-up for PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) investment picks
-Conference Call Today at 8:30 am ET- SOUTH PLAINFIELD, N.J. , Aug.
Sign-up for PTC Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update investment picks
SOUTH PLAINFIELD, N.J. , July 24, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2014 financial results and provide an update on the company's business and outlook on Thursday, August 7, 2014 at 8:30 a.m. (ET) before the opening of the market.
Sign-up for PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2014 Financial Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: PSEG Long Island Reminds Customers to be Cautious of Scams and Imposters to PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2014 Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices